HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12
9/23/2026
Impact: 75
Healthcare
HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on TriSalus Life Sciences (NASDAQ: TLSI) and raised the price target from $11 to $12.
AI summary, not financial advice
Share: